Sign in
Taking peopleNo phase

Evaluation of a Physical Device for Medical Use (ADTPM 1) for Opioid Withdrawal Symptoms

Key facts

Who runs it
Nu Eyne Co., Ltd.
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
24 people, planned
Started
30 May 2025
Planned end
6 Apr 2026
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • Neurostimulation
  • Sham stimulation
Record updated
22 July 2025

Who can take part

Age
19 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Participants aged 19 to 80 years
  • Participants currently dependent on opioids, whether prescribed or non-prescribed
  • Participants who meet the criteria for opioid use disorder (OUD) according to DSM-5
  • Participants with a Clinical Opiate Withdrawal Scale (COWS) score of 5 or higher
  • Participants with a Numeric Rating Scale (NRS) pain score of less than 6
  • Participants who have voluntarily decided to participate in the study and have provided written informed consent
  • Participants who are willing to comply with the study protocol

Who cannot take part

  • Participants who have used long-acting opioids, such as methadone or buprenorphine, continuously for more than 5 days prior to screening
  • Participants who have used methadone within 30 days prior to screening
  • Participants who have used buprenorphine within 7 days prior to screening
  • Participants with physiological dependence on alcohol or drugs other than opioids, tobacco, or marijuana
  • Participants with implanted devices such as a pacemaker, cochlear implant, or neurostimulator
  • Participants who are currently undergoing chemotherapy (Exception: Participation may be allowed if the investigator determines that participation poses no medical safety concerns for the participant)
  • Participants with implanted metal or electronic devices in the head or neck area, including deep brain stimulators or pacemakers, as specified in the product precautions and contraindications (dental implants are exempt)
  • Participants with cognitive impairment due to neurodevelopmental disorders (e.g., intellectual disability, developmental disorders, autism spectrum disorder) or neurodegenerative disorders (e.g., Alzheimer's disease, vascular dementia) that would make it difficult to undergo treatment with the investigational medical device
  • Participants who are currently participating in another clinical trial or who have participated in another clinical trial within 30 days prior to screening
  • Participants with any current uncontrolled or clinically significant medical condition
  • Participants with a history of seizures or epilepsy
  • Participants with a history of neurological disorders or traumatic brain injury
  • Participants diagnosed with a major psychiatric disorder (psychosis, schizophrenia, or bipolar disorder)
  • Participants with abnormal ear anatomy or ear infections
  • Participants diagnosed with renal or hepatic failure
  • Participants who are currently hospitalized due to a recent suicide attempt or who are persistently expressing suicidal intent
  • Participants who are currently engaged in high-risk occupations (e.g., transportation workers, crane operators, heavy machinery operators, individuals working with sharp objects, or those requiring a high level of cognitive functioning)
  • Participants who are pregnant or breastfeeding
  • Female participants of childbearing potential who do not agree to abstain from sexual intercourse or to use medically accepted contraception* during the study period; *Medically accepted methods of contraception include: condoms, consistent oral contraceptive use (≥3 months use), injectables or implantable contraceptives, or intrauterine devices (IUDs)
  • Participants who, in the opinion of the investigator, are deemed inappropriate for participation due to ethical concerns or potential impacts on study outcomes

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 19 and 80 years old?

This trial is currently available in South Korea.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to evaluate the safety and efficacy of a physical device for medical use (ADTPM 1) applied to opioid withdrawal symptoms.

The 2 groups in the trial

  • Experimental GroupTreatment being tested

    Experimental Group (Active Stimulation, n=12): Participants in this group will use the physical device for medical use (ADTPM 1) applied to the auricular region (ear and surrounding area) for 60 minutes (±10 minutes) per session, at least once daily and a minimum of 7 times per week, over a 4-week treatment period. Additional sessions may be conducted if participants require further relief of withdrawal symptoms. All assessments and permitted concomitant treatments will be administered in accordance with the study protocol.

    Treatment: Neurostimulation

  • Control GroupSham treatment, for comparison

    Control Group (Sham Stimulation, n=12): Participants in this group will use a sham stimulation device that does not deliver active stimulation. The sham device will be applied under the same schedule and conditions-60 minutes (±10 minutes) per session, at least once daily and 7 times per week for 4 weeks. All assessments and permitted concomitant treatments will be identical to those in the active stimulation group.

    Treatment: Sham stimulation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Single Center, Double-Blind, Randomized, Sham-Controlled, Parallel Design, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of a Medical Device for the Treatment of Opioid Withdrawal Symptoms
Criteria questions
Built from NCT07079215, who can take part
Record updated
22 July 2025